Alector Obtains Series A Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    953 Indiana Street San Francisco, CA 94107
  • Company Description
    Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The proceeds from this financing will enable Alector to begin research and development on innovative targets.
  • M&A Terms
  • Venture Investor
    Polaris Partners
  • Venture Investor
    OrbiMed Advisors